- Home
- TRVI
as 12-18-2024 10:00am EST
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 211.4M | IPO Year: | 2019 |
| Target Price: | $9.31 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $4.60 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Trevi Therapeutics Inc. News
TRVI Breaking Stock News: Dive into TRVI Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Trevi Therapeutics Prices $50 Million Underwritten Offering
PR Newswire
2 days ago
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
Clinical Trials Arena
5 days ago
Trevi’s chronic cough trial in IPF subjects continues without sample size change
MT Newswires
6 days ago
Sector Update: Health Care Stocks Softer Thursday Afternoon
MT Newswires
6 days ago
Top Midday Gainers
MT Newswires
6 days ago
Sector Update: Health Care
Benzinga
6 days ago
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?
MT Newswires
6 days ago
Trevi Therapeutics Reaches 75% of Enrollment Target for Phase 2B IPF Chronic Cough Study
Compare TRVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRVI Trevi Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.